Entrada Therapeutics TRDA
NASDAQ TRDA
$5.38 -0.30 (-5.28%)
At close: Oct 2, 2026 · 4:00 PM EDT

Entrada Therapeutics (TRDA) Price to FCF (2023)

Updated

Entrada Therapeutics' Price to FCF was 3.76 in Q4 2023, down 20.6% from the prior quarter.

Analysis

Entrada Therapeutics (TRDA) Price to FCF (2023) Analysis & Trends

From Q1 2023 onward, Entrada Therapeutics has reported Price to FCF for 4 quarters.

  • Per Business Quant data, TRDA's Price to FCF in the three quarters before Q4 2023 was 4.74 (Q3 2023), 4.62 (Q2 2023) and 3.79 (Q1 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Entrada Therapeutics 209.48 Mn 209.48 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 3.76
Sep 30, 2023 4.74
Jun 30, 2023 4.62
Mar 31, 2023 3.79
API Access

Entrada Therapeutics Price to FCF API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-fcf&ticker=TRDA&period=max&api_key=YOUR_API_KEY